Cencora, Inc. (NYSE:COR - Get Free Report) EVP Elizabeth S. Campbell sold 4,127 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. This represents a 21.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Cencora Trading Up 1.1 %
Shares of NYSE COR opened at $271.32 on Thursday. The company has a market cap of $52.61 billion, a price-to-earnings ratio of 38.59, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The stock's 50 day simple moving average is $252.47 and its 200 day simple moving average is $240.68. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $271.86.
Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.81%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio (DPR) is 31.29%.
Institutional Investors Weigh In On Cencora
Several large investors have recently made changes to their positions in COR. Norges Bank acquired a new position in shares of Cencora during the fourth quarter worth approximately $478,309,000. Bank of America Corp DE boosted its position in Cencora by 62.3% during the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock worth $1,166,944,000 after acquiring an additional 1,994,256 shares during the period. Castlekeep Investment Advisors LLC acquired a new position in Cencora during the 4th quarter worth $399,508,000. Raymond James Financial Inc. bought a new position in shares of Cencora in the fourth quarter worth $322,460,000. Finally, Invesco Ltd. increased its holdings in shares of Cencora by 20.4% during the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after purchasing an additional 550,246 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.
Wall Street Analyst Weigh In
COR has been the subject of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Evercore ISI boosted their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Mizuho initiated coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Finally, StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $280.20.
Read Our Latest Stock Analysis on COR
About Cencora
(
Get Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
